Why the study?
Blood pressure control remains unsatisfactorily low despite pharmacotherapies, and the field of device-based therapies for hypertension is subject to constant change.
Device-based therapies for resistant hypertension remain investigational and are not recommended for routine clinical use by current guidelines.
Device-based therapies for resistant hypertension remain investigational; leaves open their role in practice pending randomized outcome trials.
Arterial hypertension is associated with increased cardiovascular morbidity and mortality. Although blood pressure-lowering therapies significantly reduce the risk of major cardiovascular events, blood pressure control remains unsatisfactorily low. Several device-based antihypertensive therapies have been investigated in patients with treatment-resistant hypertension and in patients unable or unwilling to adhere to antihypertensive medication. As the field of device-based therapies is subject to constant change, this review aims at providing an up-to-date overview of different device-based approaches for the treatment of hypertension. These approaches target the sympathetic nervous system (renal denervation, baroreflex amplification therapy, baroreflex activation therapy, and carotid body ablation) or alter mechanical arterial properties by creating an iliac arteriovenous fistula. Notably, the use of all of these treatment options is not recommended for the routine treatment of hypertension by current guidelines but should be investigated in the context of controlled clinical studies.
No takes yet. Share an insight, caveat, or question.
Kunz et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: